109904 ⎘
dsDNA viruses; Details; Herpesviridae; Simplexvirus, e.g. human herpesvirus 1, 2 Demonstrated effect
Compositions and Methods for Delivering CFTR Polypeptides
#2Viral Vectors for Cancer Therapy
#3MACROPHAGE POLARIZING ONCOLYTIC HERPES SIMPLEX VIRUS FOR CANCER THERAPY
#4METHOD FOR TREATING GLIOMA WITH OHSV2
#5Compositions and Methods for the Treatment of Congenital Ichthyoses
#6HSV VECTORS
#7RECOMBINANT IMMUNE COMPLEXES TARGETING HERPES SIMPLEX VIRUS
#8TRANSCRIPTIONAL AND TRANSLATIONAL DUAL REGULATED ONCOLYTIC HERPES SIMPLEX VIRUS VECTORS
#9NON-TOXIC HSV VECTORS FOR EFFICIENT GENE DELIVERY APPLICATIONS AND COMPLEMENTING CELLS FOR THEIR PRODUCTION
#10Viral Vectors for Cancer Therapy
#11ONCOLYTIC VIRUSES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER
#12VACCINE COMPOSITIONS OF HERPESVIRUS ENVELOPE PROTEIN COMBINATIONS TO INDUCE IMMUNE RESPONSE
#13ONCOLYTIC VIRUS AND USES THEREOF
#14UNIVERSAL RETARGETING OF ONCOLYTIC HSV
#15PSEUDORABIES VIRUS VACCINE
#16ONCOLYTIC VIROTHERAPY WITH INDUCED ANTI-TUMOR IMMUNITY
#17IMMUNOTHERAPEUTIC VIRUS FOR THE TREATMENT OF CANCER
#18VIRUSES ENGINEERED TO PROMOTE THANOTRANSMISSION AND THEIR USE IN TREATING CANCER
#19VIRAL VECTORS FOR CANCER THERAPY
#20Replication-competent controlled alpha-herpesvirus vectors and uses therefore
#21Viral vectors for cancer therapy
#22ONCOLYTIC VIRUS COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
#23RAPID VACCINE PLATFORM
#24COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONGENITAL ICHTHYOSES
#25NEW GENERATION REGULATABLE FUSOGENIC ONCOLYTIC HERPES SIMPLEX VIRUS TYPE 1 VIRUS AND METHODS OF USE
#26Viral vectors for cancer therapy
#27NON-TOXIC HSV VECTORS FOR EFFICIENT GENE DELIVERY APPLICATIONS AND COMPLEMENTING CELLS FOR THEIR PRODUCTION
#28USE OF ONCOLYTIC VIRUSES FOR THE TREATMENT OF CANCER
#29PASSIVE TRANSFER OF IMMUNITY USING RECOMBINANT HERPES SIMPLEX VIRUS 2 (HSV-2) VACCINE VECTORS
#30COMPOSITIONS AND METHODS FOR DELIVERING CFTR POLYPEPTIDES
#31VACCINE VECTOR ENCODING MUTATED GNAQ FOR TREATMENT OF UVEAL MELANOMA AND CANCERS HAVING ONCOGENIC MUTATIONS ON GNAQ AND GNA11 PROTEINS
#32VACCINE COMPOSITIONS OF HERPESVIRUS ENVELOPE PROTEIN COMBINATIONS TO INDUCE IMMUNE RESPONSE
#33Oncolytic HSV vector
#34Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens
#35COMPOSITIONS AND METHODS FOR DELIVERING CFTR POLYPEPTIDES
#36Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
#37Rev-dependent lentiviral vaccine particles for reducing viral rebound and viral reservoirs in vivo
#38Compositions and methods for delivering CFTR polypeptides
#39STEM CELL DELIVERED ONCOLYTIC HERPES SIMPLEX VIRUS AND METHODS FOR TREATING BRAIN TUMORS
#40Therapeutic compositions and methods of use for treating cancer
#41Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
#42Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits
#43Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
#44Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
#45Purification of herpes virus
#46NON-TOXIC HSV VECTORS FOR EFFICIENT GENE DELIVERY APPLICATIONS AND COMPLEMENTING CELLS FOR THEIR PRODUCTION
#47Methods of enhancing translation ability and stability of RNA molecules, treatments, and kits
#48Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
#49Oncolytic HSV vector
#50Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
#51Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
#52Anterograde multi-synaptic transneuronal tracer
#53Use of phospholipid scramblase inhibitors for modulating inflammatory immune responses
#54Oncolytic virus therapy for resistant tumors
#55Oncolytic HSV1 vector and methods of use
#56THERAPEUTIC COMPOSITIONS AND METHODS OF USE FOR TREATING CANCER
#57Viral vectors and their use in therapeutic methods
#58Oncolytic HSV vector
#59Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
#60Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
#61Oncolytic HSV vector
#62Purification of herpes virus
#63STEM CELL DELIVERED ONCOLYTIC HERPES SIMPLEX VIRUS AND METHODS FOR TREATING BRAIN TUMORS
#64Oncolytic HSV vector
#65Method to kill pathogenic microbes in a patient
#66Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
#67Non-toxic HSV vectors for efficient gene delivery applications and complementing cells for their production
#68Neuroattenuated herpes simplex virus
#69TRPV1 modulatory gene product that affects TRPV1-specific pain behavioral responses identified in a functional screen of an HSV-based cDNA library
#70ONCOLYTIC VIRUS ENCODING PD-1 BINDING AGENTS AND USES OF THE SAME
#71Oncolytic virus therapy for resistant tumors
#72Mutant herpes simplex virus-2 for cancer therapy
#73Recombinant herpes virus and pharmaceutical composition containing the same
#74Viral vectors and their use in therapeutic methods
#75Viral vectors and their use in therapeutic methods
#76Vaccine for treatment and prevention of herpes simplex virus infection
#77Use of mutant Herpes Simplex Virus-2 for cancer therapy
#78Herpes simplex virus vaccine compositions and methods of production and use thereof